Can a stimulant drug stop Binge-Eating relapse? new study tests LDX

NCT ID NCT03926052

Completed Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the drug lisdexamfetamine (LDX) can help adults with binge-eating disorder and obesity avoid relapse. 61 participants who initially responded to treatment were randomly assigned to receive LDX or a placebo for 12 weeks. The main goal was to see if LDX reduced the number of binge-eating episodes compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lisdexamfetamine (LDX)
What this could lead to: If it works, this could provide a medication option to help people with binge-eating disorder maintain control and avoid relapse after initial treatment.
What could go wrong: This is a small, completed Phase 3 trial with only 61 participants, so results may not apply to everyone. LDX is a stimulant and can have side effects like increased heart rate or risk of misuse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BINGE-EATING DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

binge eating disorder Binge-Eating Disorder Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BINGE-EATING DISORDER OBESITY

Contacts and locations

Locations

Yale Department of Psychiatry

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.